Simufilam

Simufilam (PTI-125) is an experimental medication for the treatment of Alzheimer's disease that was being developed by the American pharmaceutical firm Cassava Sciences. Its development was discontinued in November 2024 after it failed to show clinical benefit during phase III clinical trials.
Wikipedia contributors, "Simufilam", Wikipedia, revision 1386709172, retrieved 20 November 2026, source, CC BY-SA 4.0.